Want to join the conversation?
Focus Diagnostics, the products business of $DGX, received FDA 501(k) clearance for its Simplexa Flu A/B & RSV Direct Kit. The kit can detect 46 additional influenza A/B strains and seven additional RSV strains. The approval increases the number of flu and RSV strains that Simplexa can detect to 92, the most for any FDA-cleared molecular test kit.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.